Latest Articles
Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR) - The Manila Times
Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR) The Manila Times
Published: June 24, 2026, 10:48 a.m.
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026 - riauone.com
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026 riauone.com
Published: June 15, 2026, 12:29 p.m.
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026 - The Manila Times
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026 The Manila Times
Published: June 14, 2026, 10:21 p.m.
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026 - NTB Kommunikasjon
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026 NTB Kommunikasjon
Published: June 14, 2026, 10:05 p.m.
ABSI: ABS-201 advances in phase II trials, targeting major unmet needs in hair loss and endometriosis - TradingView
ABSI: ABS-201 advances in phase II trials, targeting major unmet needs in hair loss and endometriosis TradingView
Published: June 9, 2026, 8:01 p.m.
Maipl Therapeutics Advances Non-Hormonal Oral Endometriosis Therapy Targeting Prostaglandin F2α Receptor - Femtech Insider
Maipl Therapeutics Advances Non-Hormonal Oral Endometriosis Therapy Targeting Prostaglandin F2α Receptor Femtech Insider
Published: May 15, 2026, 11:33 a.m.
Endometriosis Has a Metabolism Problem, and Targeting It Could Transform Treatment - The American Journal of Managed Care® (AJMC®)
Endometriosis Has a Metabolism Problem, and Targeting It Could Transform Treatment The American Journal of Managed Care® (AJMC®)
Published: May 8, 2026, 4:51 p.m.
Endometriosis Has a Metabolism Problem, and Targeting It Could Transform Treatment - AJMC
Endometriosis Has a Metabolism Problem, and Targeting It Could Transform Treatment AJMC
Published: May 8, 2026, 4:51 p.m.
Arrivent Announces Ind Clearance For Novel Tetravalent Muc16/Napi2b Targeting Adc Arr-002 With Initial Focus In Ovarian And Endometrial Cancers - TradingView
Arrivent Announces Ind Clearance For Novel Tetravalent Muc16/Napi2b Targeting Adc Arr-002 With Initial Focus In Ovarian And Endometrial Cancers TradingView
Published: May 7, 2026, 12:05 p.m.
Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha - Targeting ADC at AACR Annual Meeting 2026 - riauone.com
Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha - Targeting ADC at AACR Annual Meeting 2026 riauone.com
Published: April 24, 2026, 4:01 a.m.
Link copied to clipboard!